Efficacy of a Pseudomonas aeruginosa serogroup O9 vaccine
Infection and Immunity · 2023
DOI: 10.1128/iai.00247-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Infection and Immunity, 2023. Verfasst von Dina A Moustafa und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Pulmonary, Asthma, Cystic Fibrosis, and Sleep, Emory University School of Medicine, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: O Antigens, Pseudomonas Infections. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, HHS | National Institutes of Health, Cystic Fibrosis Foundation.
Abstract (Originalsprache)
There are currently no approved vaccines against the opportunistic pathogen Pseudomonas aeruginosa . Among vaccine targets, the lipopolysaccharide (LPS) O antigen of P. aeruginosa is the most immunodominant protective candidate. There are 20 different O antigens composed of different repeat sugar structures conferring serogroup specificity, and 10 are found most frequently in infection. Thus, one approach to combat infection by P. aeruginosa could be to generate immunity with a vaccine cocktail that includes all these serogroups. Serogroup O9 is 1 of the 10 serogroups commonly found in infection, but it has never been developed into a vaccine, due in part to the acid-labile nature of the O9 polysaccharide. Our laboratory has previously shown that intranasal administration of an attenuated Salmonella strain expressing the P. aeruginosa serogroup O11 LPS O antigen was effective in clearing bacteria and preventing mortality in mice following intranasal challenge with serogroup O11 P. aeruginosa . Consequently, we set out to develop a P. aeruginosa serogroup O9 vaccine using a similar approach. Here, we show that Salmonella expressing serogroup O9 triggered an antibody-mediated immune response following intranasal administration to mice and that it conferred protection from P. aeruginosa serogroup O9 in a murine model of acute pneumonia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Division of Pulmonary, Asthma, Cystic Fibrosis, and Sleep, Emory University School of Medicine, Atlanta, Georgia, USA.
- Emory+Children's Center for Cystic Fibrosis and Airway Disease Research, Emory University School of Medicine, Atlanta, Georgia, USA.
- Department of Microbiology, Immunology, and Cancer Biology, University of Virginia Health System, Charlottesville, Virginia, USA.
- Microbiology and Molecular Genetics Program, Graduate Division of Biological and Biomedical Sciences, Laney Graduate School, Emory University, Atlanta, Georgia, USA.
ORCID-Profile: Dina A Moustafa, Antonio DiGiandomenico, Joanna B Goldberg
Förderung
- NIAID NIH HHS
- HHS | National Institutes of Health
- Cystic Fibrosis Foundation
Zitieren
APA
Moustafa, D. A., DiGiandomenico, A., Raghuram, V., Schulman, M., Scarff, J. M., Davis, M. R., Varga, J. J., Dean, C. R., & Goldberg, J. B. (2023). Efficacy of a Pseudomonas aeruginosa serogroup O9 vaccine. Infection and Immunity. https://doi.org/10.1128/iai.00247-23
Vancouver
Moustafa DA, DiGiandomenico A, Raghuram V, Schulman M, Scarff JM, Davis MR, et al. Efficacy of a Pseudomonas aeruginosa serogroup O9 vaccine. Infection and Immunity. 2023. doi:10.1128/iai.00247-23
BibTeX
@article{Moustafa2023,
author = {Moustafa, Dina A and DiGiandomenico, Antonio and Raghuram, Vishnu and Schulman, Marc and Scarff, Jennifer M and Davis, Michael R and Varga, John J and Dean, Charles R and Goldberg, Joanna B},
title = {Efficacy of a Pseudomonas aeruginosa serogroup O9 vaccine},
journal = {Infection and Immunity},
year = {2023},
doi = {10.1128/iai.00247-23}
}
EUVIMED